Kazia KZIA 深 滬
等待開盤 10-04 09:30:00 美东时间
6.56
+0.250
+3.96%
華盛通- 最 高6.67
- 今 開6.25
- 成交量 8.75万股
- 最 低 6.20
- 昨 收 6.31
- 總市值 1061.93万
- 52周最高 39.05
- 市盈率 靜 --
- 換手率 5.41%
- 52周最低 2.90
- 委 比 72.36%
- 總股本 161.88万
- 歷史最高 744.50
- 量 比 0.15
- 振 幅 7.45%
- 歷史最低 3.005
- 每 手 1
- 風險率 0.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股机会日报 | 9月非农数据悬了？今晚或将无法按计划发布；“木头姐”本周持续加仓阿里、百度
美国政府停摆！9月非农数据悬了？今晚或将无法按计划发布；看好中国科技股AI叙事，“木头姐”本周持续加仓阿里、百度；英伟达对阿联酋芯片出口交易陷入停滞>>
10-03 19:07
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
10-03 14:32
Kazia Therapeutics Announces Its Participation In A Fully Funded Australian Medical Research Future Fund Project Titled "Sequential & Temporal Therapeutic Agility For The Treatment Of Diffuse Midline Glioma"
Kazia Therapeutics Limited (NASDAQ:KZIA), a clinical-stage biotechnology company developing innovative therapies for brain cancers, today announced its participation in a fully funded Australian Medical Research Future Fund (MRFF) project titled "Sequential & Temporal Therapeutic Agility for the Treatment of Diff
10-01 21:23
Kazia Therapeutics' Paxalisib Shows Complete Disruption Of Metastatic Cell Clusters In Stage IV HER2-Positive Breast Cancer Study
Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer.In this ex vivo
09-11 20:05
KANZHUN LIMITED Announces Upsizing and Extension of Share Repurchase Program
KANZHUN LIMITED (BOSS Zhipin) announced the upgrade and extension of its share repurchase program, increasing the authorized repurchase amount from US$150 million to US$250 million and extending the program period to August 28, 2026.
08-20 11:15
Kazia Therapeutics Announces At the Market Offering Agreement
Kazia Therapeutics ( ($KZIA) ) has shared an update. On July 25, 2025, Kazia Th...
07-26 05:17
Kazia Therapeutics Announces Preliminary Results From First Patient In Phase 1b Trial Evaluating Combination Regimen Of Paxalisib, Pembrolizumab, And Standard Chemotherapy After Completing Cycle 1 Of Dosing
Kazia Therapeutics (NASDAQ:KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard
07-09 20:03
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
Maxim Group Maintains Buy on Kazia Therapeutics, Maintains $15 Price Target
Maxim Group analyst Jason McCarthy maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $15 price target.
06-12 01:32
Kazia Therapeutics Announces That First Patient Has Been Dosed In Phase 1b Trial Of Paxalisib In Advanced Breast Cancer
Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve patient outcomes in advanced breast cancer Kazia
06-05 20:05
